<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116047</url>
  </required_header>
  <id_info>
    <org_study_id>RG 14-093</org_study_id>
    <secondary_id>2014-003389-26</secondary_id>
    <secondary_id>ISRCTN41478539</secondary_id>
    <nct_id>NCT04116047</nct_id>
  </id_info>
  <brief_title>CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)</brief_title>
  <acronym>CompARE</acronym>
  <official_title>Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive,
      Multi-Arm, Multi-Stage (MAMS) design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CompARE Trial examines alternative regimens for escalating treatment of intermediate and
      high-risk oropharyngeal cancer in an adult patient population. The aim is to assess whether
      escalated radiotherapy, adding surgery or immunotherapy will improve overall survival and
      quality of life in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Overall survival (OS)</measure>
    <time_frame>from randomisation until date of death from any cause (follow-up until 8 years post-treatment)</time_frame>
    <description>defined as the interval in whole days between date of randomisation and date of death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Event Free Survival (EFS)</measure>
    <time_frame>From randomisation until date of progression/persistence/recurrence/death (follow-up until 8 years post-treatment)</time_frame>
    <description>defined as the interval in whole days between date of randomisation until date of progression/persistence/recurrence/death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Acute (&lt;3 months post-treatment) toxicity events experienced</measure>
    <time_frame>From date of randomisation until 2 year follow-up</time_frame>
    <description>Total number of acute (&lt;3 months post-treatment) severe (grade 3-5) toxicity events experienced. Adverse events will be collected post-treatment and graded according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of late (up to 2 years post-treatment) toxicity events experienced using CTCAE</measure>
    <time_frame>From date of randomisation until 2 year follow-up</time_frame>
    <description>Severe (grade 3-5) adverse events will be collected up to 2 years post randomisation, these events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and version 3.0 for scoring mucositis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of late (up to 2 years post-treatment) toxicity events experienced using RTOG</measure>
    <time_frame>From date of randomisation until 2 year follow-up</time_frame>
    <description>Late and severe toxicity events at 2 years post randomisation,will be collected and graded using Radiation Therapy Oncology Group (RTOG) Radiation Morbidity Scoring Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head and neck specific quality of life at 2 years post-randomisation using EORTC C30</measure>
    <time_frame>From date of randomisation until 2 year follow-up</time_frame>
    <description>Patients will complete the European Organisation for Research and Treatment of Cancer (EORTC) C30 questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head and neck specific Quality of Life at 2 years post-randomisation</measure>
    <time_frame>From date of randomisation until 2 year follow-up</time_frame>
    <description>Patients will complete the European Organisation for Research and Treatment of Cancer (EORTC) H&amp;N35 questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallowing outcomes assessed using MDADI Questionnaire at 24 months post-chemoradiotherapy</measure>
    <time_frame>From date of randomisation until 2 year follow-up</time_frame>
    <description>Patients will complete the M.D. Anderson Dysphagia Inventory (MDADI) Questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Percutaneous Endoscopic Gastrostomy (PEG) use</measure>
    <time_frame>From date of randomisation until 2 year follow-up</time_frame>
    <description>PEG use will be assessed at baseline, throughout treatment and during 2 year follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness of treatment as assessed using EuroQol Group (EQ-5D) questionnaire</measure>
    <time_frame>From date of randomisation until 2 year follow-up</time_frame>
    <description>Patients will complete the EuroQol Group (EQ-5D) questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complication rates in each arm for patients who require a neck dissection at 4 months following the 3 month post-chemoradiotherapy assessment scan.</measure>
    <time_frame>At 4 months following the 3 month post-chemoradiotherapy scan</time_frame>
    <description>Surgical complication rates will be assessed at trial visits if a neck dissection is required at 4 months post-chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">695</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 (control): chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concomitant chemoradiotherapy, 3-weekly cisplatin 100mg/m2 or weekly 40mg/m2 with Intensity Modulated Radiotherapy (IMRT) using 70 gray (Gy) in 35F(fractions) +/- neck dissection as indicated by clinical and radiological assessment 3-months post treatment. This is the international gold standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Dose-escalated chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalated chemoradiotherapy using intensity modulated radiotherapy (IMRT) 64Gy in 25F + Cisplatin 100mg/m2 day 1 of week 1 and of week 5 or weekly 40mg/m2. Neck dissection as indicated by clinical and radiological assessment at 3-months post-treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Durvalumab + Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of induction durvalumab 1500mg by intravenous (IV) infusion followed by arm 1 within four weeks. Within one-two weeks after the completion of arm 1, durvalumab 1500mg every four weeks will be initiated for a total of 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Arm 1 (control): chemoradiotherapy</arm_group_label>
    <arm_group_label>Arm 3: Dose-escalated chemoradiotherapy</arm_group_label>
    <arm_group_label>Arm 5: Durvalumab + Arm 1</arm_group_label>
    <other_name>CDDP, Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <arm_group_label>Arm 5: Durvalumab + Arm 1</arm_group_label>
    <other_name>MEDI-4736, Imfinzi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Arm 1 (control): chemoradiotherapy</arm_group_label>
    <arm_group_label>Arm 5: Durvalumab + Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dose-escalated radiotherapy</intervention_name>
    <arm_group_label>Arm 3: Dose-escalated chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Oropharyngeal squamous cell carcinoma (OPSCC) in base of tongue and tonsil with a
             Multidisciplinary Team (MDT) recommendation for treatment with definitive concurrent
             chemoradiotherapy

          2. All OPC T4 or N3 (HPV+ and HPV-) OR all HPV -ve (negative) OPC T1-T4, N1-N3 or T3-4,
             N0 OR HPV +ve (positive) OPC T1-T4 with N2b-N3 nodes AND who are smokers ≥ 10 pack
             years current or previous smoking history

          3. Minimum life expectancy of 3 months

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          5. Adequate renal function, glomerular filtration rate (GFR) &gt;50ml/min calculated using
             Cockcroft-Gault formula

          6. Adequate bone marrow function (absolute neutrophil count (ANC) ≥1.5 x 109/L,
             haemoglobin ≥9.0g/dL and platelets ≥100 x 109/L)

          7. Adequate liver function i.e. plasma bilirubin ≤1.5 times the upper limit of normal
             (ULN), and alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤2.5 x ULN

          8. Prothrombin time (PT) ≤1.5 x ULN or International Normalised Ratio (INR) ≤1. 5

          9. Magnesium ≥ lower limit of normal

         10. No cancers in previous 5 years, except basal cell carcinoma of skin and cervical
             intra-epithelial neoplasia (CIN)

         11. Aged 18-70

         12. Written informed consent given for the trial

         13. Surgically resectable disease if being randomised to all four arms

         14. Females must either be of non-reproductive potential (i.e. post-menopausal by history:
             ≥55 years old and no menses for ≥1 year without an alternative medical cause; or
             history of hysterectomy, or history of bilateral tubal ligation or history of
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry

         15. Willingness to comply with the protocol for the duration of the study, including
             undergoing treatment and scheduled visits and examinations including follow up

        Exclusion Criteria:

          1. All T1-T2,N0 OPC (HPV +ve or HPV-ve)

          2. HPV positive patients who are:

             T1-T3, N0-N2c non-smokers T1-T3, N0-N2c smokers with ≤10 pack years or T1-T2, N0-N2a
             smokers with ≥10 pack years

          3. Unfit for chemoradiotherapy regimens

          4. Creatinine Clearance &lt;50ml/min

          5. Treatment with any of the following, prior to randomisation:

               1. Any Investigational Medicinal Products (IMP) within 30 days

               2. Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks

               3. Major surgery within 4 weeks

          6. History of allergic reactions to any of the IMPs and excipients used in this trial

          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
             bleeding diatheses including any subject known to have evidence of acute or chronic
             hepatitis B, hepatitis C, Human Immunodeficiency Virus (HIV), or psychiatric
             illness/social situations that would limit compliance with study requirements or
             compromise the ability of the subject to give written informed consent

          8. Women who are pregnant or breast-feeding. Women of child- bearing potential must have
             a negative pregnancy test performed within 7 days prior to randomisation

          9. Men or women who are not prepared to practise methods of contraception of proven
             efficacy during treatment and for 6 months following the end of treatment

         10. Any condition that, in the opinion of the Investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results

             Additional Exclusion Criteria for Arm 5 only:

         11. Any previous treatment with PD-L or PD-L1 inhibitor, including durvalumab

         12. Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid dose

         13. Active or prior documented autoimmune or inflammatory disorders including inflammatory
             bowel disease e.g. colitis or Crohn's disease, diverticulitis (with the exception of
             diverticulosis), celiac disease, systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis). The following are exceptions to this criterion:

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the study physician

         14. Patients with an active non-infectious pneumonitis

         15. History of primary immunodeficiency

         16. History of allogeneic organ transplant

         17. Known history of previous clinical diagnosis of tuberculosis

         18. Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving durvalumab. Inactivated viruses, such as those in the influenza
             vaccine, are permitted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Mehanna</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Firth</last_name>
    <email>CompARE@trials.bham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isla Humphreys</last_name>
    <email>CompARE@trials.bham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hwang, MRCP FRCR</last_name>
    </contact>
    <investigator>
      <last_name>David Hwang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>East Midlands</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <state>East Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorcan O'Toole, MRCPI, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Lorcan O'Toole</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colchester General Hospital</name>
      <address>
        <city>Colchester</city>
        <state>Essex</state>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivienne Loo, MRCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Vivienne Loo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <state>Essex</state>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Ward, MRCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Amy Ward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muthiah Sivaramalingam, RCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Muthiah Sivaramalingam, M</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>North Yorkshire</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor Aynsley, MRCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Eleanor Aynsley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>North Yorkshire</state>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Prestwich, FRCR, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Robin Prestwich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketan Shah, MRMCP,FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Ketan Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Foran, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Bernadette Foran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Kovarik, Oncology</last_name>
    </contact>
    <investigator>
      <last_name>Josef Kovarik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hartley, MRCP, FRCP</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Hartley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry</name>
      <address>
        <city>Coventry</city>
        <state>West Midlands</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newcross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <zip>WV10 OQP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ho, FRCS (OMFS)</last_name>
    </contact>
    <investigator>
      <last_name>Michael Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Sen, MRCP, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mehmet Sen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Moleron, MBBS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Moleron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fionnuala Houghton, MRCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Fionnuala Houghton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoda Al-Booz, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Hoda Al-Booz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi Jadon, FRCR, MRCP</last_name>
    </contact>
    <investigator>
      <last_name>Rashmi Jadon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Chester, MRCP,FRCP</last_name>
    </contact>
    <investigator>
      <last_name>John Chester</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devraj Srinivasan, MRCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Devraj Srinivasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Jones, FRCSEd, FRCS</last_name>
    </contact>
    <investigator>
      <last_name>Terry Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Middlesex Hospital</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Thompson, MRCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Anna Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew McPartlin, MD FRCR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinos Geropantas, MBBS, CCT</last_name>
    </contact>
    <investigator>
      <last_name>Dinos Geropantas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Griffin, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Goranova, MRCP,FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Rebecca Goranova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Pettit, MRCP,FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Laura Pettit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Banner, MRCP,FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Russell Banner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Jankowska, MRCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Petra Jankowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Chambers, MRCP, FRCR</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Chambers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Brammer, MRCP,FRCP</last_name>
    </contact>
    <investigator>
      <last_name>Caroline Brammer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oropharyngeal cancer</keyword>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

